x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Cell & Gene: The Podcast

Cell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.

science life sciences

All Episodes

14:18

Pioneering Next-Gen TCR Therapies in Solid Tumors...

Cell & Gene: The Podcast ·

2024/10/10

We love to hear from our listeners. Send us a message.Carsten Linnemann, Ph.D., CEO of Neogene Therapeutics and Head of Oncology Cell Therapy Clinical Development, AstraZeneca joins Cell & Gene: The Podcast’s Erin Harris to discuss T-cell receptor (TCR) therapies for solid cancers. They talk through key challenges and opportunities in developing TCR therapies targeting neoantigens as well as the potential benefits of TCR-T therapies for cancer treatment. Linnemann shares his thoughts on the

en

22:00

Optogenetics for Vision Restoration with Ray...

Cell & Gene: The Podcast ·

2024/09/25

We love to hear from our listeners. Send us a message.Ray Therapeutics' Co-Founder and CEO, Paul Bresge, joins Host Erin Harris to talk about optogenetics and how the company’s optogenetics approach differs from other gene therapies on the market developed to restore vision in retinal diseases like retinitis pigmentosa.

en

28:06

A New Approach to Genome Engineering with Tessera...

Cell & Gene: The Podcast ·

2024/09/12

We love to hear from our listeners. Send us a message.Tessera Therapeutics' CEO, Dr. Michael Severino, joins Host Erin Harris to discuss Gene Writing, the biotech's genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source. Severino discusses why delivery has always been a challenge for gene editing technologies and why Gene Writing is different when it comes to efficient delivery.

en

25:13

Scaling Allo with Allogene Therapeutics' Dr. Zachary...

Cell & Gene: The Podcast ·

2024/08/29

We love to hear from our listeners. Send us a message.Allogene Therapeutics' EVP of R&D and CMO, Dr. Zachary Roberts, penned an original article for Cell & Gene titled, The Path Forward for CLL is Allogeneic. In his article, Dr. Roberts explains that chronic lymphocytic leukemia (CLL) is the most common leukemia in the U.S. And that while CLL remains a disease that is managed, it is not one that is often cured. In this episode, Host Erin Harris follows up Roberts' article with in-dept...

en

27:58

CGT Regulatory Update and Outlook with Dark Horse...

Cell & Gene: The Podcast ·

2024/08/15

We love to hear from our listeners. Send us a message.Applications (BLAs) of recent approvals and complete responses for novel products or rare diseases as well as BLAs currently under review. Benton shares information about FDA Draft Gudiances, including Platform Technology Designation Program for Drug Development: Guidance for Industry. She also provides a regulatory outlook for CGT developers.

en

29:55

Identifying Drug Development Opportunities for DMD...

Cell & Gene: The Podcast ·

2024/08/01

We love to hear from our listeners. Send us a message.Debra Miller, CEO and Founder and Dr. Michael Kelly, Chief Scientific Officer at CureDuchenne talk to Host Erin Harris about the FDA approval for the expansion to the label indication for ELEVIDYS from Sarepta Therapeutics as well as how CureDuchenne works with various biotechs developing gene therapies for Duchenne muscular dystrophy (DMD). Miller and Kelly also share their advice and recommendations for companies developing drugs for DMD...

en

21:01

Tackling "The Delivery Problem" of Gene Editing-Based...

Cell & Gene: The Podcast ·

2024/07/18

We love to hear from our listeners. Send us a message.Lucas Harrington, Co-Founder and Chief Scientific Officer of Mammoth Biosciences, joins Erin Harris to shed light on the biotech's proprietary ultracompact CRISPR systems to develop potential long-term curative therapies for patients with life-threatening and debilitating diseases. They discuss why in vivo delivery continues to be a bottleneck against the clinical advancement of gene-editing-based medicines and what ultracompact CRISPR sys...

en

35:30

TILs for the Treatment of Solid Tumors with KSQ...

Cell & Gene: The Podcast ·

2024/07/04

We love to hear from our listeners. Send us a message.KSQ Therapeutics' CSO, Micah Benson, Ph.D., joins Erin Harris to discuss how Tumor-Infiltrating Lymphocytes (TILs) as a treatment modality have the potential to treat a variety of solid tumor types. Benson explains KSQ's Phase 1/2 clinical study, KSQ-001EX, which consists of TILs in which the SOCS1 gene is inactivated by CRISPR/Cas9 gene editing. In addition to solid tumors, Benson also addresses the therapeutic potential for autoimmune di...

en

27:52

Synthetic Biology and Programmable mRNA with Strand...

Cell & Gene: The Podcast ·

2024/06/20

We love to hear from our listeners. Send us a message.Strand Therapeutics' CEO and Co-Founder Jake Becraft joins Erin Harris to discuss genetic regulation and how the company's programmable mRNA constructs combine genes for self-replication derived from RNA viruses with genetically programmed logic circuits that control the location, timing, and intensity of expression of therapeutic proteins within the patient’s body, enabling precise and controlled delivery. They also cover the role synthet...

en

14:52

Developing an mRNA Therapy for DMD with Elixirgen...

Cell & Gene: The Podcast ·

2024/06/06

We love to hear from our listeners. Send us a message.Elixirgen Therapeutics' Aki Ko joins Erin Harris to detail the company's Bobcat mRNA therapeutic and how it differs from traditional exon-skipping drugs and AAV-microdystrophin in treating DMD. Regarding delivery, Ko explains the advantage of the mRNA approach over the AAV approach.

en

25:21

The Current State of the Global Regulatory Landscape...

Cell & Gene: The Podcast ·

2024/05/28

We love to hear from our listeners. Send us a message.Dr. Bambi Grilley is Professor of Pediatrics and the Director of Clinical Research and Early Product Development for the Center of Cell and Gene Therapy (CAGT) at Baylor College of Medicine AND she is Chief Regulatory Officer at ISCT. Dr. Grilley talks to us about her role as CRO at ISCT and the global regulatory landscape for cell and gene therapies. She takes a deep dive into the pediatric patient journey, and she shares her expectations...

en

31:49

Dr. Bruce Levine on ISCT and the Future of CAR-T

Cell & Gene: The Podcast ·

2024/05/23

We love to hear from our listeners. Send us a message.In anticipation of ISCT 2024 in Vancouver, Canada, Dr. Bruce Levine is back on Cell & Gene: The Podcast to share information about the event as well as his expertise on the future of CAR-T therapy for solid tumors, autoimmune disease, and more. He talks about his time and learnings as President Elect, President, and Immediate Past President of ISCT. He covers Cellicon Valley and Philadelphia's success as on-going CGT hub, and much more.

en

18:51

CGTs for HIV Suppression with Addimmune's Dr. Marcus...

Cell & Gene: The Podcast ·

2024/05/09

We love to hear from our listeners. Send us a message.Dr. Marcus Conant is CMO at Addimmune, a biotech startup developing a cell therapy for HIV that spun out of cell and gene therapy biotech American Gene Technologies (AGT). He spent his career on the front lines of HIV treatment and research and remains an advocate for the HIV patient. He formed the Kaposi’s Sarcoma Research & Education Foundation in 1982, which later became the San Francisco AIDS Foundation. On this episode, Dr. Conant...

en

29:39

Inside BlueRock Therapeutics' Parkinson's Disease...

Cell & Gene: The Podcast ·

2024/04/25

BlueRock Therapeutics' SVP Head of Development, Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company's phase I clinical trial for Parkinson’s disease, which continues to show positive trends at 18 months. They cover the important role induced pluripotent stem cells' (iPSCs) play in the trial, and they also discuss the company's investigational cell therapy, bemdaneprocel.Listen and subscribe so you never miss an episode!

en

23:08

Reducing the Disease Burden of AML with Vor Bio's Dr....

Cell & Gene: The Podcast ·

2024/04/11

en

19:37

Reducing Toxicities in Allogeneic Cell Therapies with...

Cell & Gene: The Podcast ·

2024/03/28

en

17:17

Inside Cellular Rejuvenation Therapies for...

Cell & Gene: The Podcast ·

2024/03/14

en

27:31

The Future of Rare Diseases with The Jackson...

Cell & Gene: The Podcast ·

2024/02/29

en

20:48

Inside Yescarta's Reduced Median Turnaround Time with...

Cell & Gene: The Podcast ·

2024/02/15

en

37:17

Pricing, Value, And Access of CGTs With The Dedham...

Cell & Gene: The Podcast ·

2024/02/01

en

128 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter